FOXO4-DRI vs SHLP-6
Comparison of FOXO4-DRI (Very Low evidence) and SHLP-6 (Low evidence).
Last updated: February 12, 2026
FOXO4-DRI
SHLP-6
Overview
FOXO4-DRI and SHLP-6 are both studied in the peptide research space.
FOXO4-DRI: A D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction, selectively eliminating senescent cells (senolytic).
SHLP-6: A 22-amino acid mitochondria-derived peptide with the unique property of being pro-apoptotic—the opposite of its sister peptides humanin and SHLP-2.
Evidence Comparison
| Aspect | FOXO4-DRI | SHLP-6 |
|---|---|---|
| Evidence Level | Very Low | Low |
| Human Studies | 0 | 1 |
| Preclinical Studies | 14 | 11 |
| Total Sources | 18 | 12 |
Key Differences
| Aspect | FOXO4-DRI | SHLP-6 |
|---|---|---|
| Category | Longevity | Longevity |
| Evidence Strength | Very Low | Low |
| Total Sources | 18 | 12 |
| Human Studies | 0 | 1 |
Summary
- FOXO4-DRI: Very Low evidence with 18 total sources (0 human)
- SHLP-6: Low evidence with 12 total sources (1 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.